Basal 5-HIAA levels in prepubescent and adult male progeny prenatally exposed to fluoxetine
| Treatment Group | 5-HIAA Level | ||||
|---|---|---|---|---|---|
| Frontal cortex | Hypothalamus | Hippocampus | Striatum | Midbrain | |
| pmol/mg protein | |||||
| Prepubescent | |||||
| Saline | 23.6 ± 2.1 (8) | 36.2 ± 0.9 (8) | 21.3 ± 1.0 (7) | 37.2 ± 2.8 (8) | 52.5 ± 2.4 (8) |
| Fluoxetine | 23.6 ± 2.1 (8) | 35.3 ± 2.6 (7) | 20.5 ± 1.0 (8) | 32.9 ± 1.9 (8) | 51.2 ± 3.6 (7) |
| Adult | |||||
| Saline | 20.0 ± 1.5 (8) | 28.5 ± 2.4 (8)* | 14.9 ± 0.8 (8)* | 23.0 ± 1.7 (8)* | 34.4 ± 3.3 (7)* |
| Fluoxetine | 22.0 ± 1.5 (8) | 27.6 ± 1.5 (8)* | 14.0 ± 0.9 (8)* | 22.1 ± 1.4 (8)* | 33.3 ± 3.0 (8)* |
Data represent the means ± S.E.M. from seven or eight saline-challenged rats per group, with each rat within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure to fluoxetine (10 mg/kg/2 ml s.c., to dams from GD 13 to GD 20) did not alter basal 5-HIAA content in the frontal cortex, hypothalamus, hippocampus, striatum or midbrain of prepubescent male progeny. Likewise, 5-HIAA content was not altered in adult male progeny across any of the brain regions examined. Data from each brain region were analyzed separately, using two-way analysis of variance, followed by Newman-Keuls post hoc test.
* Significantly different from the respective values obtained in prepubescent progeny (P < .05).